Addressing these limitations through further research may clarify the therapeutic potential of targeting FABP7 in a tumor-specific manner, especially given the growing interest in developing novel FABP7 inhibitors [67] and advancing cancer immunotherapy [68,69]. The gene discussed is FABP7; the disease is neoplasm.